Krsnaa Diagnostics Reports Q2 Net Profit of ₹24.60 Crore and Revenue of ₹271 Crore

Market snapshot: Krsnaa Diagnostics Limited has announced its consolidated quarterly financial results, posting revenue from operations of ₹271 crore and a net profit of ₹24.60 crore for the second quarter.

Data Snapshot

• Q2 consolidated revenue from operations grew to ₹271 crore compared to ₹206 crore in the year-ago period.
• Q2 consolidated net profit reached ₹24.60 crore, up from ₹24 crore in Q2 of the previous fiscal year.

What's Changed

• Q2 revenue increased by 31.55% YoY to ₹271 crore from ₹206 crore (derived: ₹271 cr vs ₹206 cr).
• Q2 net profit grew by 2.50% YoY to ₹24.60 crore from ₹24 crore (derived: ₹24.60 cr vs ₹24 cr).

Key Takeaways

• Top-line revenue expanded significantly by 31.55% YoY to ₹271 crore.
• Bottom-line profit after tax recorded a modest 2.50% YoY rise to ₹24.60 crore.
• Operational volume scaling across public-private partnership networks drove top-line expansion.

SAHI Perspective

Krsnaa Diagnostics displayed strong top-line trajectory with revenue expanding over 31% YoY. However, net profit growth remained modest at 2.50% YoY, reflecting operating costs and initial setup expenses linked to newly operationalized diagnostic projects across regional networks.

Market Implications

The robust top-line performance highlights ongoing diagnostic volume expansion across public health partnerships, while steady profit margins underline operational discipline during ongoing network deployment.

Trading Signals

Market Bias: Bullish

Robust top-line expansion of 31.55% YoY to ₹271 crore demonstrates volume scale across PPP networks, while net profit grew 2.50% YoY to ₹24.60 crore.

Overweight: Healthcare Facilities, Diagnostics

Trigger Factors:

• Sustained volume growth across operational diagnostic centers
• Margin improvement as recently launched regional contracts mature

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian diagnostics space continues to benefit from institutional healthcare expansion and public-private partnership contracts that drive test volume growth in Tier-II and Tier-III markets.

Key Risks to Watch

• Elongated working capital cycles associated with government contract receivables.
• Initial operational cost drag during onboarding phase of newly won diagnostic concessions.

Recent Developments

In October 2026, Krsnaa Diagnostics announced a strategic AI collaboration with AZmed for radiology imaging efficiency. Additionally, in September 2026, the company executed a concession agreement for PET-CT diagnostic facilities in Punjab.

Closing Insight

Krsnaa Diagnostics' revenue expansion reinforces its execution in the PPP diagnostic market; monitoring profit margin improvement as new facilities mature remains critical.

High Performance Trading with SAHI.